Yesterday marked one year since the World Health Organization declared COVID-19 a global pandemic. (
NPR)
As of 8:00 a.m. ET on Friday, the unofficial COVID-19 toll in the U.S. reached 29,286,650 cases and 530,829 deaths up 131,603 and 1,562 respectively, since this time yesterday.
Adding tocilizumab (Actemra) to remdesivir (Veklury) failed to shorten time to discharge in patients hospitalized with severe COVID-19 pneumonia, Genentech announced.
Following reports of blood clots in people getting the Oxford-AstraZeneca vaccine, several countries have paused use and the European Medicines Agency is launching an investigation. (
CNN)
But other nations, including Australia, want the U.S. to send the tens of millions of doses it s currently sitting on. (
email article
Though the push is on to make at-home COVID-19 tests much more widely available, patients and their clinicians should be aware of downsides that could diminish their accuracy, experts from the College of American Pathologists warned at a news conference Thursday.
They cautioned that in addition to being uncomfortable to administer at home and possibly not covered by insurance, such tests may produce inadequate sample material and could be damaged by improper handling, thus producing false results.
It s also unclear whether any or some of the at-home tests particularly those detecting viral antigens are capable of picking up all of the variants that are increasingly circulating around the country, they said.
Share this article
Share this article
DOYLESTOWN, Pa., March 10, 2021 /PRNewswire/ FlowMetric Life Sciences, Inc., a global leader in immunology testing services, has launched a fleet of mobile COVID-19 testing labs capable of testing up to 300 individuals per day at any time and at any physical location. The fully functioning mobile units combine the accuracy of modern testing technology with the convenience of on-site screening, delivering clinical test results within an hour.
First developed for military field-testing operations, the mobile testing labs (1 RV and 7 self-contained mobile pods) are designed to deploy to any school, university or business campus. Since launch, the labs have performed thousands of rapid antigen tests in back-to-campus testing initiatives for several regional school districts and universities. Additionally, the labs are being deployed to regional sports teams to meet the growing need for the rigorous and more frequent NCAA COVID-19 testing requ
Medical Diagnostic Laboratories, L.L.C., (MDL), member of Genesis Biotechnology Group
® (GBG) and CLIA-certified, CAP-accredited laboratory specializing in high-complexity, state-of-the-art, automated DNA-based molecular analyses, launched a new line of testing for the field of Urology. This testing, available through
Uroveda Institute of Urogenital Diseases, an MDL Center of Excellence, blends DNA-based molecular testing with traditional pathology and cytology tests to aid in diagnosing or screening for urologic conditions.
Genesis Biotechnology Group
According to the National Institutes of Health (NIH), medical care costs for urologic diseases in the United States neared $11 billion in 2020. Urologic malignancies such as prostate, bladder, and renal cancers present challenges in diagnoses, treatment decisions, monitoring, and recurrence testing. Prostate, bladder, and renal cancers rank second, seventh, and ninth, respectively, in the top 10 cancers in the US based on new
A sneak peek of the current state and future use of artificial intelligence in pathology
Mar 8 2021
Artificial intelligence can already scan images of the eye to assess patients for diabetic retinopathy, a leading cause of vision loss, and find evidence of strokes on brain CT scans. But what does the future hold for this emerging technology? How will it change how doctors diagnose disease, and how will it improve the care patients receive?
Artificial intelligence will have a dramatic impact on the field of pathology, a team of top experts predicts. Image Credit: UVA Health
A team of doctors led by UVA Health’s James H. Harrison Jr., MD, PhD, has given us a glimpse of tomorrow in a new article on the current state and future use of artificial intelligence (AI) in the field of pathology. Harrison and other members of the College of American Pathologists’ Machine Learning Workgroup have spent the last two years evaluating the potential of AI and machine learning, assessing its c